BIOMARIN PHARMACEUTICAL INC Convertible Debt
BIOMARIN PHARMACEUTICAL INC (BMRN) had Convertible Debt of $597.18 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Balance Sheet › Liabilities › Debt › Long-Term Debt, Unclassified
us-gaap:ConvertibleDebt · last filed 2026-02-26
- 2025-12-31: Convertible Debt $597.18M.
- 2025-09-30: Convertible Debt $596.66M.
- 2025-06-30: Convertible Debt $596.16M.
- 2025-03-31: Convertible Debt $595.65M.
| Period end | Convertible Debt | Convertible Debt as first filed |
|---|---|---|
| 2025-12-31 | $597.18M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $596.66M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $596.16M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $595.65M 10-Q · filed 2025-05-02 | |
| 2024-12-31 | $595.14M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $594.63M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $1.09B 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $1.09B 10-Q · filed 2024-04-26 | |
| 2023-12-31 | $1.09B 10-K · filed 2025-02-24 | |
| 2023-09-30 | $1.09B 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $1.08B 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $1.08B 10-Q · filed 2023-04-28 | |
| 2022-12-31 | $1.08B 10-K · filed 2024-02-26 | |
| 2022-09-30 | $1.08B 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $1.08B 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $1.08B 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $1.08B 10-K · filed 2023-02-27 | |
| 2021-09-30 | $1.08B 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $1.08B 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $1.08B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $1.08B 10-K · filed 2022-02-25 | |
| 2020-09-30 | $1.45B 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $1.44B 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $852.68M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $848.12M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $843.62M 10-Q/A · filed 2019-11-04 | |
| 2019-06-30 | $839.16M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $834.77M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $830.42M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $1.20B 10-Q · filed 2018-10-26 | |
| 2018-06-30 | $1.19B 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $1.18B 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $1.17B 10-K · filed 2019-02-28 | |
| 2017-09-30 | $1.17B 10-Q · filed 2017-10-31 | |
| 2017-06-30 | $676.21M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $690.93M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $683.24M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $675.64M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $670.11M 10-Q · filed 2016-08-08 | |
| 2015-12-31 | $683.24M 10-Q · filed 2017-05-04 | $662.29M 10-Q · filed 2016-08-08 |
| 2013-12-31 | $655.57M 10-K · filed 2014-02-26 | |
| 2013-09-30 | $78.31M 10-Q · filed 2013-10-28 | |
| 2013-06-30 | $109.82M 10-Q · filed 2013-07-29 | |
| 2013-03-31 | $109.85M 10-Q · filed 2013-04-29 | |
| 2012-12-31 | $348.22M 10-K · filed 2014-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |